Response: Commentary: An In Silico–In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

Ähnliche Einträge

• An in silico—in vitro Pipeline Identifying an HLA-A(*)02:01(+) KRAS G12V(+) Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients
  von: Mishto, Michele, et al.
  Veröffentlicht: (2019)
• Commentary: An In Silico – In Vitro Pipeline Identifying an HLA-A*02:01(+) KRAS G12V(+) Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients
  von: Beer, Ilan
  Veröffentlicht: (2021)
• The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing
  von: Textoris-Taube, Kathrin, et al.
  Veröffentlicht: (2015)
• HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
  von: Khor, Seik-Soon, et al.
  Veröffentlicht: (2021)
• Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope
  von: Nguyen, Thi HO, et al.
  Veröffentlicht: (2017)